288 related articles for article (PubMed ID: 34426106)
1. Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial.
Fakharian A; Barati S; Mirenayat M; Rezaei M; Haseli S; Torkaman P; Yousefian S; Dastan A; Jamaati H; Dastan F
Int Immunopharmacol; 2021 Oct; 99():107961. PubMed ID: 34426106
[TBL] [Abstract][Full Text] [Related]
2. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.
Izumo T; Kuse N; Awano N; Tone M; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Matsumoto H; Inomata M
Respir Investig; 2021 Nov; 59(6):799-803. PubMed ID: 34413006
[TBL] [Abstract][Full Text] [Related]
4. Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.
Mehta HB; An H; Andersen KM; Mansour O; Madhira V; Rashidi ES; Bates B; Setoguchi S; Joseph C; Kocis PT; Moffitt R; Bennett TD; Chute CG; Garibaldi BT; Alexander GC;
Ann Intern Med; 2021 Oct; 174(10):1395-1403. PubMed ID: 34399060
[TBL] [Abstract][Full Text] [Related]
5. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
[TBL] [Abstract][Full Text] [Related]
6. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
[TBL] [Abstract][Full Text] [Related]
8. Real-life use of remdesivir in hospitalized patients with COVID-19.
Garcia-Vidal C; Meira F; Cózar-Llistó A; Dueñas G; Puerta-Alcalde P; Garcia-Pouton N; Chumbita M; Cardozo C; Hernandez-Meneses M; Alonso-Navarro R; Rico V; Agüero D; Bodro M; Morata L; Jordan C; Lopera C; Ambrosioni J; Segui F; Grafia N; Castro P; García F; Mensa J; Martínez JA; Sanjuan G; Soriano A;
Rev Esp Quimioter; 2021 Apr; 34(2):136-140. PubMed ID: 33675220
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study.
Joo EJ; Ko JH; Kim SE; Kang SJ; Baek JH; Heo EY; Shi HJ; Eom JS; Choe PG; Bae S; Ra SH; Kim DY; Kim BN; Kang YM; Kim JY; Chung JW; Chang HH; Bae S; Cheon S; Park Y; Choi H; Lee E; Lee BY; Park JW; Sohn Y; Heo JY; Kim SH; Peck KR
J Korean Med Sci; 2021 Mar; 36(11):e83. PubMed ID: 33754512
[TBL] [Abstract][Full Text] [Related]
10. Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact.
Béraud G; Timsit JF; Leleu H
PLoS One; 2022; 17(1):e0262462. PubMed ID: 35020746
[TBL] [Abstract][Full Text] [Related]
11. Remdesivir for severe covid-19: a clinical practice guideline.
Rochwerg B; Agarwal A; Zeng L; Leo YS; Appiah JA; Agoritsas T; Bartoszko J; Brignardello-Petersen R; Ergan B; Ge L; Geduld H; Gershengorn HB; Manai H; Huang M; Lamontagne F; Kanda S; Kawano-Dourado L; Kurian L; Kwizera A; Murthy S; Qadir N; Siemieniuk R; Silvestre MA; Vandvik PO; Ye Z; Zeraatkar D; Guyatt G
BMJ; 2020 Jul; 370():m2924. PubMed ID: 32732352
[TBL] [Abstract][Full Text] [Related]
12. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
[TBL] [Abstract][Full Text] [Related]
13. Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients.
Seyfi S; Latifi K; Amri Male P; Sadeghi Haddad Zavareh M; Ezoji K; Mohammadnia-Afrozi M
Int Immunopharmacol; 2021 Dec; 101(Pt B):108241. PubMed ID: 34688151
[TBL] [Abstract][Full Text] [Related]
14. Use of Remdesivir in Myasthenia gravis and COVID-19.
Peters BJ; Rabinstein AA; DuBrock HM
Pharmacotherapy; 2021 Jun; 41(6):546-550. PubMed ID: 33835512
[TBL] [Abstract][Full Text] [Related]
15. A case report of COVID-19 in refractory myasthenia: Outcome with remdesivir and dexamethasone.
Bhagavan SM; Ramaswamy SB; Govindarajan R
Medicine (Baltimore); 2021 May; 100(18):e25701. PubMed ID: 33950951
[TBL] [Abstract][Full Text] [Related]
16. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.
Ali K; Azher T; Baqi M; Binnie A; Borgia S; Carrier FM; Cavayas YA; Chagnon N; Cheng MP; Conly J; Costiniuk C; Daley P; Daneman N; Douglas J; Downey C; Duan E; Duceppe E; Durand M; English S; Farjou G; Fera E; Fontela P; Fowler R; Fralick M; Geagea A; Grant J; Harrison LB; Havey T; Hoang H; Kelly LE; Keynan Y; Khwaja K; Klein G; Klein M; Kolan C; Kronfli N; Lamontagne F; Lau R; Fralick M; Lee TC; Lee N; Lim R; Longo S; Lostun A; MacIntyre E; Malhamé I; Mangof K; McGuinty M; Mergler S; Munan MP; Murthy S; O'Neil C; Ovakim D; Papenburg J; Parhar K; Parvathy SN; Patel C; Perez-Patrigeon S; Pinto R; Rajakumaran S; Rishu A; Roba-Oshin M; Rushton M; Saleem M; Salvadori M; Scherr K; Schwartz K; Semret M; Silverman M; Singh A; Sligl W; Smith S; Somayaji R; Tan DHS; Tobin S; Todd M; Tran TV; Tremblay A; Tsang J; Turgeon A; Vakil E; Weatherald J; Yansouni C; Zarychanski R; ;
CMAJ; 2022 Feb; 194(7):E242-E251. PubMed ID: 35045989
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021.
Ayodele O; Ren K; Zhao J; Signorovitch J; Jonsson Funk M; Zhu J; Bao Y; Gondek K; Keenan H;
PLoS One; 2021; 16(12):e0261707. PubMed ID: 34962924
[TBL] [Abstract][Full Text] [Related]
20. Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach.
Hazard D; Kaier K; von Cube M; Grodd M; Bugiera L; Lambert J; Wolkewitz M
BMC Med Res Methodol; 2020 Aug; 20(1):206. PubMed ID: 32781984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
